SOLY - Soliton, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
10.46
+0.74 (+7.61%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close9.72
Open9.96
Bid10.31 x 800
Ask10.46 x 900
Day's Range9.95 - 10.73
52 Week Range4.12 - 29.00
Volume421,775
Avg. Volume2,065,982
Market Cap157.001M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.66
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire

    Dr. Michael Kaminer Presented Soliton RAP for Cellulite at Key Dermatology Conference

    HOUSTON , Aug. 16, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed ...

  • PR Newswire

    Soliton Treats First Patients in Pivotal Cellulite Trial

    HOUSTON, Aug. 14, 2019 /PRNewswire/ -- Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that the Company has treated the first patients in its pivotal cellulite trial. Cellulite affects up to 90% of women and over a billion dollars per year is spent on treatment in the U.S.  Results from our initial proof of concept clinical trial suggest the potential for a new approach to treating cellulite.

  • PR Newswire

    Soliton Announces Patient Recruitment Has Begun for Pivotal Cellulite Trial

    HOUSTON, Aug. 12, 2019 /PRNewswire/ -- Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that the Company has initiated patient recruitment for its upcoming pivotal cellulite trial across all four trial sites. The Company is seeking approximately 60 patients to enroll in the trial.

  • PR Newswire

    Soliton Completes Site Enrollment and Conducts Initial Site Training to Start Pivotal Cellulite Trial

    HOUSTON, Aug. 6, 2019 /PRNewswire/ -- Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that the company has completed their site initiation visit for the first site to be included in its upcoming expanded pivotal Cellulite Trial.  Site initiation visits are for initial clinical staff training and protocol reviews with the staff in advance of patient treatments.  The company also announced that patient enrollment for the trial has been initiated at the initial trial site.

  • PR Newswire

    Soliton Partners with Clear Dermatology and Aesthetics Center to Advance Pivotal Cellulite Trial

    HOUSTON , Aug. 5, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed ...

  • PR Newswire

    Soliton Announces Global Nasdaq Partner Sanmina Delivers RAP Device to More Effectively Target Cellulite Reduction for Pivotal Trial

    HOUSTON, Aug. 1, 2019 /PRNewswire/ -- Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that Sanmina, Corp., the Company's global manufacturing partner has delivered the Company's second generation rapid acoustic pulse ("Gen 2 RAP") device for use in the upcoming pivotal trial targeting cellulite reduction.

  • PR Newswire

    Soliton Announces IRB Approval

    HOUSTON, July 29, 2019 /PRNewswire/ -- Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that the company has received approval for the trial protocol from the independent Institutional Review Board ("IRB") for its upcoming pivotal Cellulite Trial.

  • PR Newswire

    Soliton Enlists Chicago Cosmetic Surgery and Dermatology to Advance Pivotal Cellulite Trial

    HOUSTON, July 25, 2019 /PRNewswire/ -- Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that the company has identified a third site as well as the supervising physician for its upcoming expanded pivotal Cellulite Trial.  The site joins two previously identified sites in what is anticipated to be a four-site trial. The expanded Cellulite Clinical Trial builds upon a proof-of-concept trial conducted earlier this year.  Subjects will be treated at Chicago Cosmetic Surgery and Dermatology with treatment supervised by Omer Ibrahim, MD FAAD and Carolyn I. Jacob, MD FAAD, both Board Certified Dermatologists.  The data from the patients treated in Chicago will be added to the data from patients treated at Capital Laser in Chevy Chase, MD and at SkinCare Physicians in Boston.

  • PR Newswire

    Soliton's FDA Cleared Device is Granted Key Patent

    European Patent Office Approves Core Patent Covering Soliton's RAP Technology HOUSTON , July 23, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical ...

  • Why Soliton Stock Is Falling Today
    Motley Fool

    Why Soliton Stock Is Falling Today

    The roller coaster ride continues.

  • PR Newswire

    Soliton Announces Positive 26-week Cellulite Clinical Trial Results Demonstrate Long-Term Improvement

    HOUSTON, July 15, 2019 /PRNewswire/ -- Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced additional positive data from its proof of concept clinical trial for the reduction of cellulite.

  • PR Newswire

    Soliton Expands Clinical Trial Sites to include SkinCare Physicians

    HOUSTON, July 10, 2019 /PRNewswire/ -- Soliton, Inc. (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that the company has identified an additional site and supervising physician for its upcoming expanded pivotal Cellulite Trial. The site is the second of four planned sites for the pivotal trial.

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For July 9, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Soliton, Inc. (NASDAQ: SOLY ) shares were ...

  • PR Newswire

    Soliton to Announce Cellulite Trial Data for 26-Week Period on July 15, 2019

    HOUSTON, July 8, 2019 /PRNewswire/ -- Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that it will release the cumulative 26-week patient data from its cellulite proof of concept clinical trial on Monday, July 15, 2019.  As the Company has previously announced, the proof-of-concept clinical trial studied the safety and efficacy of a new version of its acoustic shockwave device for the treatment of moderate to severe cellulite.  The results from the 26-week assessment are being presented at The Aesthetics Show in Las Vegas on July 12, 2019.

  • PR Newswire

    Soliton Announces Filing of Form S-1 Registering the Shares Issued in Private Placement at $14.00 per Unit

    HOUSTON, July 2, 2019 /PRNewswire/ -- Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced the filing of a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC).  This filing with the SEC is intended to register for resale the common stock underyling the $9.45 million of units sold at $14.00 per unit, which unit consists of one share of the Company's common stock and and a warrant to purchase .70 shares of common stock at $16.00 per share. This private placement was previously completed on June 19, 2019.

  • PR Newswire

    Soliton Partners with Capital Laser and Skin Care to Advance Pivotal Cellulite Trial

    HOUSTON, July 1, 2019 /PRNewswire/ -- Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that the company has partnered with a Maryland-based site as well as the supervising physician for its upcoming expanded pivotal Cellulite Trial.  The trial builds upon the proof-of-concept trial conducted earlier this year.

  • Benzinga

    18 Stocks Joining The Russell Indices

    The Russell 2000 Index is a small-cap stock market index that includes the bottom 2,000 companies found in the Russell 3000 index. The Russell Microcap Index includes the 1,000 smallest securities found ...

  • PR Newswire

    Soliton's Inclusion in the Russell 2000 and 3000 will be Effective After the Close of the Market Today

    HOUSTON, June 28, 2019 /PRNewswire/ -- Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that the company will be added to the Russell 2000® and 3000® Indexes, effective after the market close on Friday, June 28, 2019, as part of the Russell Indexes annual reconstitution. The Russell Index rebalancing represented over $97 Billion in the closing moments of trading before the 2018 Russell reconstition.

  • PR Newswire

    Soliton Engages CRO to begin Pivotal Cellulite Trial

    HOUSTON, June 25, 2019 /PRNewswire/ -- Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that the company has retained Emergent Clinical Consulting, LLC to serve as the Company's Contract Research Organization ("CRO") and manage its upcoming pivotal Cellulite Trial.

  • PR Newswire

    Soliton to be Added to the Russell 2000 and 3000 Indexes on June 28, 2019

    HOUSTON, June 18, 2019 /PRNewswire/ -- Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that the company will be added to the Russell 2000® and 3000® Indexes, effective after the market close on Friday, June 28, 2019, as part of the Russell Indexes annual reconstitution.

  • PR Newswire

    Soliton Announces $9.45 Million Private Placement

    HOUSTON, June 17, 2019 /PRNewswire/ -- Soliton, Inc. (SOLY), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that it has entered into definitive agreements with certain institutional and accredited investors to raise aggregate gross proceeds of approximately $9.45 million through the private placement of its equity securities. The financing was led by Remeditex Ventures, LLC, the Company's largest shareholder, which agreed to purchase $5.0 million of the securities in the private placement.

  • PR Newswire

    Soliton Announces Long-Term Cellulite Trial Results to be Presented at The Aesthetics Show on July 11-14, 2019

    HOUSTON, June 12, 2019 /PRNewswire/ -- Soliton, Inc. (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that Dr. Omer Ibrahim of Chicago Cosmetic Surgery and Dermatology will present 26-week data from its completed proof-of-concept cellulite clinical trial at The Aesthetics Show dermatology conference in Las Vegas, Nevada, to be held July 11-14, 2019.

  • PR Newswire

    Soliton Confirms Conference Call to Discuss Recently Announced Significant Discovery and FDA Clearance for Today at 4:30 PM ET

    HOUSTON, June 11, 2019 /PRNewswire/ -- Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), will conduct a webcast to discuss its recent announcements regarding its significant discovery of acoustic subcision and its 510(k) clearance for its acoustic shockwave RAP device. Interested parties can access the live webcast on the Company's website under the Investors section at http://ir.soliton.com.

  • PR Newswire

    Soliton Announces Conference Call to Discuss Recently Announced Significant Discovery and FDA Clearance

    HOUSTON, June 5, 2019 /PRNewswire/ -- Soliton, Inc., (SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), will conduct a webcast to discuss its recent announcements regarding its significant discovery of acoustic subcision and its 510(k) clearance for its acoustic shockwave RAP device. Interested parties can access the live webcast on the Company's website under the Investors section at http://ir.soliton.com.

  • Soliton Announces Significant Discovery of Acoustic Subcision for Treatment of Cellulite
    PR Newswire

    Soliton Announces Significant Discovery of Acoustic Subcision for Treatment of Cellulite

    RAP technology combines selective disruption of fibrotic structures with production of new collagen in single non-invasive procedure HOUSTON , June 4, 2019 /PRNewswire/ -- Soliton, Inc., (NASDAQ: SOLY) ...